SUN Pharmaceutical Industries, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: SUN Pharmaceutical Industries, Inc Pharmaceutical Import Records from India — 19 Products, $33.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Pharmaceutical Industries, Inc — Pharmaceutical Importer Profile (2026) | 19 Products, $33.2M Trade | TransData Nexus

SUN Pharmaceutical Industries, Inc

Pharmaceutical Importer · United States · Respiratory Focus · $33.2M Total Trade · DGFT Verified

SUN Pharmaceutical Industries, Inc is a pharmaceutical importer based in United States with a total trade value of $33.2M across 19 products in 10 therapeutic categories. Based on 866 verified import shipments from Indian Customs (DGFT) records, SUN Pharmaceutical Industries, Inc is the #1 buyer in 1 product including Lenalidomide. SUN Pharmaceutical Industries, Inc sources from 2 verified Indian suppliers, with Sun Pharmaceutical Industries Limited accounting for 89.6% of imports.

SUN Pharmaceutical Industries, Inc — Import Portfolio & Supplier Network

SUN Pharmaceutical Industries, Inc import network — 19 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Pharmaceutical Industries, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$1.3M	41	89.6%
Alembic Pharmaceuticals Limited	$150.0K	3	10.4%

SUN Pharmaceutical Industries, Inc sources from 2 verified Indian suppliers across .

What Formulations Does SUN Pharmaceutical Industries, Inc Import?

Formulation	Value	Ships
Loteprednol etabonate ophthalmic	$300.0K	6
Mesalamine delayed release tablets 1.2GM[9360 packs x	$150.0K	3
Mesalamine delayed release tablets 1.2GM[6190 packs x	$145.7K	3
Desvenla er 100MG tablets	$100.0K	2
Doxorubicin hydrochloride liposome	$100.0K	2
Desmopressin acetate injection USP	$50.0K	1
Desvenla er 50MG tablets	$50.0K	1
Mesalamine delayed release tablets 1.2GM[9353 packs x 1x120's] (batch no. dne1294a, dne1282a, dne1293a, dne1284a	$50.0K	1
Mesalamine delayed release tablets 1.2GM[8864 packs x 1x120's] (batch no. dne1267a, dne1198a, dne1280a mfg.dt. 10/23	$50.0K	1
Mesalamine delayed release tablets 1.2GM[4680 packs x	$50.0K	1
Tobramycin inhalation solution USP, 300MG/ 5ML (tobramycin 300MG/5ML nebuliser solution) [768 Pack x	$50.0K	1
Chlorothiazide sodium for injection USP,0.5GM/vial (500 MG/vial) [25803 Pack x1 vial] (batch no. imc25001 & imc25002	$50.0K	1
Paliperidone extended release tablets, 6MG [11688 packs x	$49.4K	3
Budesonide inhalation suspension, 0.5 MG	$48.6K	2
Tobramycin inhalation solution USP, 300MG/ 5ML (tobramycin 300MG/5ML nebuliser solution) [440 Pack x	$48.5K	1

SUN Pharmaceutical Industries, Inc imports 22 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 19 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Mesalamine	Gastrointestinal	$6.4M	128	0.2%	6
2	Budesonide	Respiratory	$4.4M	101	1.1%	6
3	Doxorubicin	Oncology	$2.6M	53	1.3%	3
4	Ipratropium	Respiratory	$2.5M	163	3.0%	3
5	Amphotericin	Antifungals	$2.4M	48	1.0%	2
6	Ciprofloxacin	Antibiotics	$2.1M	42	0.4%	6
7	Dexamethasone	Corticosteroids	$2.1M	42	0.7%	4
8	Sunitinib	Advanced Oncology	$2.1M	42	2.3%	2
9	Formoterol	Respiratory	$1.9M	37	1.9%	3
10	Lenalidomide	Advanced Oncology	$1.2M	24	0.0%	1
11	Ofloxacin	Advanced Antibiotics	$950.0K	19	0.1%	11
12	Imatinib	Advanced Oncology	$871.0K	26	1.6%	15
13	Tobramycin	Antibiotics	$800.0K	16	1.4%	6
14	Niacin	Lipid & Metabolism	$663.1K	47	8.6%	4
15	Nitrofurantoin	Advanced Antibiotics	$646.8K	14	1.9%	9
16	Pazopanib	Advanced Oncology	$450.0K	9	3.6%	2
17	Digoxin	Cardiovascular	$438.4K	39	11.9%	2
18	Diltiazem	Cardiovascular	$357.9K	11	2.0%	15
19	Minocycline	Advanced Antibiotics	$234.9K	5	1.0%	16

SUN Pharmaceutical Industries, Inc imports 19 pharmaceutical products across 10 categories into United States totaling $33.2M. The company is the #1 buyer for 1 product: Lenalidomide.

SUN Pharmaceutical Industries, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sun Pharmaceutical Industries, Inc. is a prominent pharmaceutical company operating in the United States, specializing in the importation and distribution of finished pharmaceutical formulations. Headquartered in Cranbury, New Jersey, the company serves as a key player in the U.S. pharmaceutical supply chain, focusing on delivering a diverse range of high-quality medicines to meet various therapeutic needs. As a subsidiary of Sun Pharmaceutical Industries Limited, headquartered in Mumbai, India, Sun Pharmaceutical Industries, Inc. leverages its parent company's extensive global network and manufacturing capabilities to source and supply pharmaceutical products to the U.S. market. The company's role in the U.S. pharmaceutical distribution landscape is significant, as it collaborates with healthcare professionals, wholesalers, and distributors to ensure the availability of essential medications across the country.

2Distribution Network

Sun Pharmaceutical Industries, Inc. maintains a robust distribution network within the United States, with facilities strategically located to optimize logistics and ensure timely delivery of pharmaceutical products. The company's distribution center in Cranbury, New Jersey, serves as a central hub, facilitating efficient warehousing and distribution operations. Additionally, Sun Pharma has established distribution and customer service teams at multiple locations across the country, enhancing its ability to serve a wide geographic area effectively. This extensive network enables the company to reach various regions, ensuring that healthcare providers and patients have access to the necessary medications. Beyond the U.S., Sun Pharma's global presence spans over 100 countries, supported by 41 manufacturing facilities across five continents, reflecting its commitment to delivering high-quality, affordable medicines worldwide.

3Industry Role

In the United States pharmaceutical supply chain, Sun Pharmaceutical Industries, Inc. functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from its parent company, Sun Pharmaceutical Industries Limited, and other suppliers, importing these products into the U.S. market. Once imported, Sun Pharma distributes these medications to various stakeholders, including wholesalers, healthcare providers, and pharmacies, ensuring that a diverse range of pharmaceutical products is accessible to meet the needs of patients and healthcare professionals. This role is crucial in bridging the gap between international pharmaceutical manufacturing and the U.S. healthcare system, facilitating the availability of both generic and specialty medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Pharmaceutical Industries, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sun Pharmaceutical Industries, Inc. demonstrates a notable concentration in its sourcing strategy, primarily importing finished pharmaceutical formulations from two Indian suppliers: Sun Pharmaceutical Industries Limited and Alembic Pharmaceuticals Limited. The majority of shipments, accounting for 89.6% of the total, are sourced from Sun Pharmaceutical Industries Limited, amounting to $1.3 million across 41 shipments. Alembic Pharmaceuticals Limited contributes a smaller portion, with 3 shipments totaling $150,000, representing 10.4% of the total shipments. This sourcing pattern indicates a strong reliance on Sun Pharmaceutical Industries Limited, which may present both strategic advantages and potential risks.

The high dependency on a single supplier could lead to vulnerabilities in the supply chain, especially if disruptions occur within Sun Pharmaceutical Industries Limited. However, the established relationship and consistent supply from this supplier suggest a stable and reliable partnership. The limited engagement with Alembic Pharmaceuticals Limited may reflect strategic decisions to maintain quality control, negotiate favorable terms, or leverage existing relationships. Overall, while the sourcing concentration offers operational efficiencies, it also necessitates contingency planning to mitigate potential risks associated with supplier dependency.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for the safety, efficacy, and quality of drugs entering the U.S. market. This legislation outlines requirements for drug approval, manufacturing practices, labeling, and importation procedures. For Indian pharmaceutical companies exporting to the U.S., understanding and complying with the FDA's regulations is essential to ensure market access and avoid potential legal issues.

The FDA's regulatory framework includes specific pathways for the importation of foreign-manufactured drugs. Drugs imported into the U.S. must meet FDA standards for quality, safety, and effectiveness. The FDA reviews shipments of imported drugs to determine their admissibility, and a drug may be refused entry if it appears to be adulterated, misbranded, or unapproved. Additionally, the FDA examines and analyzes samples of imported drugs to ensure they comply with applicable standards and labeling requirements.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. All foreign drug establishments whose products are imported into the U.S. are required to register their establishment with the FDA and list all of their drug products in commercial distribution in the United States. This registration process ensures that the FDA is notified of all regulated products imported into the U.S. and facilitates the agency's oversight of these products.

SUN Pharmaceutical Industries, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sun Pharmaceutical Industries, Inc. focuses its product strategy on importing a diverse range of finished pharmaceutical formulations across multiple therapeutic areas. The company's top five imported products include Mesalamine, Budeson

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — SUN Pharmaceutical Industries, Inc

What products does SUN Pharmaceutical Industries, Inc import from India?

SUN Pharmaceutical Industries, Inc imports 19 pharmaceutical products across 10 categories. Top imports: Mesalamine ($6.4M), Budesonide ($4.4M), Doxorubicin ($2.6M), Ipratropium ($2.5M), Amphotericin ($2.4M).

Who supplies pharmaceuticals to SUN Pharmaceutical Industries, Inc from India?

SUN Pharmaceutical Industries, Inc sources from 2 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (89.6% of imports, $1.3M).

What is SUN Pharmaceutical Industries, Inc's total pharmaceutical import value?

SUN Pharmaceutical Industries, Inc's total pharmaceutical import value from India is $33.2M, based on 866 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Pharmaceutical Industries, Inc focus on?

SUN Pharmaceutical Industries, Inc imports across 10 categories. The largest: Respiratory (26.6%), Gastrointestinal (19.3%), Advanced Oncology (13.9%).

Get Full SUN Pharmaceutical Industries, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 9 company name variants from customs records. For current shipment-level data, contact TransData Nexus.